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The medical profession, in particular cardiologists, acknowledge the fact that during the last 30 years, much of the
progress made in the field of medicine has resulted from fruitful and close collaboration between academia and the
pharmaceutical industry. However, during the last decade, this relationship has changed considerably. The industry
increasingly carries out its own research, development of drugs and trials, according to its own agenda. As a result,
academia has lost its influence.
This has led to a dramatic increase in the cost of clinical randomised trials. In the meantime, academic careers and
research have become less attractive to physicians. Funding for research is increasingly devoted to basic science, in
particular genomics, and little is left for clinical research. As a result, many important clinical trials in various areas of
medicine, including cardiology, remain unfunded.
© 2003 Published by Elsevier Science Ltd on behalf of The European Society of Cardiology.
A policy conference
In June 2002 the European Society of Cardiology
(ESC) assembled important actors in the field of
cardiovascular research to a Policy Conference at
its headquarters, the European Heart House, in
Sophia Antipolis, France. Clinical investigators from
the academic world met representatives from
non industry and industry driven contract research
organisations (CRO), industrial research divisions,
European medical research councils, health
authorities, the US National Institute of Health,
the Directorate General XII of the European
Commission, European Heart Foundations, editors
in chief of prominent medical journals as well
as the leadership of ESC for two days of intense
debate. Different aspects of inadequately funded
clinical research were extensively reviewed and
discussed. The first part of the conference ad-
dressed successful achievements but also failures
in clinical trials, surveys and registries, as well as
the cost of organising clinical trials. Furthermore,
career possibilities for clinical scientists were re-
viewed. During the second and third parts of the
meeting, present funding of clinical research at
different levels, national and European, was put in
perspective and compared with the situation in the
USA. The role of Heart Foundations and alternate
means of funding were examined. This report con-
tains some of the highlights from the conference.
The full text can be found on the website of the
ESC at www.escardio.org. Excerpts from this
conference have also been published.1
The demand for physician/scientists
The declining interest and incentives in
clinical research have led to a scarcity of
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physician-scientists adequately trained in research.
Inadequate funding for clinical research leads to
lower salaries than those available in the private
sector, and less attractive career opportunities
combine to widen the gap between clinical and
basic research. Funding to clinical research in
Europe is decreasing, with budget allocations often
disproportionate to the actual burden of disease.
Promises by EU nations to increase the proportion
of the GNP devoted to research have yet to be
fulfilled. In addition, the strong position of the
industry in directing research has attracted many
physician-scientists away from academic medicine.
The industry has gradually become less dependent
on the collaboration of academia, as many large
companies now have the financial and material
capacities to carry out their own research. All in all,
the general level of interest in clinical research is
on the decline, and this situation needs to be
addressed.
Clinical research projects devoid of
funds
It is an unfortunate fact that much clinical research
is dominated by commercial interests, with the
result that many research projects of great interest
to the medical community remain unfunded be-
cause they are of little commercial interest to the
industry. There are many examples of this in all
medical disciplines, and particularly in cardiology.
Over the last few years, the ESC has made consid-
erable efforts in this area by funding surveys and
registries aimed at providing crucial information
about incidence and prevalence of cardiovascular
diseases throughout Europe. However, like many
projects, these efforts are hampered by insuf-
ficient funding. The lack of resources allocated to
clinical research must be overcome to open the
door for clinical research in scientifically useful,
but financially unrewarding areas.
The cost of clinical research
For many researchers trying to launch projects
without funding, the cost of industry-driven
research is prohibitive. Depending on the com-
plexity of the study, the number of centres, and
other factors, costs can range from 5,000 to 10,000
Euro per patient for a randomised trial organised by
the industry. Simplifying the organisational pro-
cedures could make it possible to reduce these
costs. For example, data monitoring and processing
could be carried out by networks of university-
based researchers, and other cost saving measures
could be employed to bring the cost of independent
research down to affordable levels. It is estimated
that the cost of a clinical randomised trial could be
reduced by a factor of 10 to 20, compared to
commercially driven research.
Institutional support to clinical research
In contrast to the United States, the institutions of
the European Union accord a limited portion of the
total available funding to clinical research. The
American National Institutes of Health (NIH) pro-
vide a centralised framework with considerable
financial resources, with an annual budget of 28
billion US dollars, of which 31% is allocated to
clinical research. The NIH is capable of supporting
several thousand research projects. In Europe,
however, the situation is more fragmented and
heterogeneous. There are considerable disparities
between funding allocations and research potential
in the EU member states, creating a climate in
which research is often duplicated, and insti-
tutional funding hard to obtain. From one country
to another, research varies greatly both in quality
and in quantity. The VIth Framework Programme
(FP6) of the EU aims to address these structural
problems by creating a more favourable en-
vironment for research, with better integrated
structures through networks of excellence and
simplified administrative procedures.
Overall, only a small part of the FP6 budget is
earmarked for clinical research. Within FP6, life
sciences represent only one branch, and will re-
ceive 2.25 billion Euros over a period of 5 years.
Basic science will receive a greater proportion of
available resources than clinical research, so the
concrete impact of this programme on funding for
clinical research remains to be seen.
However, centralised funding from the EU insti-
tutions are not the only possibility for finding funds
for research in Europe. Other funding channels can
be found, such as individual initiatives by EU mem-
ber states. Many nations reserve a portion of their
national budget for funding research, and these
channels have proven their efficacy in the past in
several countries.
The role of independent providers of
research funding
The role of Heart Foundations, active in fund-
raising and budget allocation for clinical research in
some European countries, is considerable. Many
European countries have very active Heart Founda-
tions that rely on diverse and innovative initiatives
among the public for raising funds. It must not be
ignored that these organisations are proof that
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proper organisation and a good understanding of
the mechanisms of fundraising can be extremely
effective in raising much-needed funds outside of
the usual structures. Possibilities for international
co-operation are hampered by the fact that there is
little or no co-ordination in fund-raising and budget
allocation across Europe, but in individual cases,
Heart Foundations are one example of an often
lucrative source of independent fund-providers.
The European Science Foundation (ESF) is an
association of major national funding agencies de-
voted to scientific and clinical research throughout
27 countries. The proposal is to pool funding from
different organisations and countries to channel it
into four to five major clinical trial projects per
year. The ESF takes the responsibility of finding
financial support from its members and affiliate
bodies. This initiative, another interesting idea
for independent funding, has not yet proven its
efficacy.
Ways into future European clinical
research
Although there are no immediate or magic solutions
to the existing problem, it is obvious that the use
of already existing resources must be optimised.
This is perhaps best done through an improved
organisation of clinical research at national and in
particular supra-national levels. An immediate
step towards a better future would therefore be
improved research co-ordination across Europe.
Furthermore it is appropriate that a larger propor-
tion of already available resources are devoted to
clinical science.
If we really want European clinical research to
compete with US efforts and others on equal terms,
a unified European research agency, mirroring the
NIH, would offer the best perspective. At present
however, there is a lack of political motivation and
vision from the EU member states. Meanwhile fund-
ing of research will continue within the context of
Framework Programmes. The amounts of such fund-
ing need to increase up to a level that acknowledges
that it is only through continued research that we
will be able to improve the health of the European
population and deal with the rising costs of health
care. Life sciences research and investigator-driven
clinical trials must move upwards on the agenda.
At national level, there is also a lack of coordi-
nation of research efforts between countries.
Besides, clinical research could be funded from
a variety of sources: from non-pharmaceutical
industry; from insurance companies, which would
gain financially from decrease in disease; from
research charities; from governments, whose
research would be made more efficient by inter-
national coordination; from the European Commis-
sion, whose present funding mechanisms may be
used in coordination with other organisations. Such
resources might be shared in a joint fund to be
established as a trust organised by an independent
party such as a professional body.
In addition, national governments and the insti-
tutions of the European Union should recognise that
there are certain clinical problems in European
society that can only be recognised by a comparison
of incidence and practice across national boun-
daries. Professional medical bodies independent of
short-term political needs, or national economic
restraints, would be the best candidates to carry
out this analysis of what studies really need to
be done for the health of European citizens,
particularly in the field of clinical trials.
Last but not least, dialogue between the
pharmaceutical industry and academics must be
re-established, to return to the fruitful relations
known in previous times, and to escape from the
often ambiguous relationship with elements of
master and servant in both directions, which
currently prevails.
The role of the ESC in this context might be to
co-ordinate networks of investigators in Europe.
One example of this is the Euro Heart Survey Pro-
gramme carried out by the ESC. However, other
very active groups already exist in Europe, such as
the GISSI group in Italy, the ALKK in Germany, the
RIKS group in Sweden and others. We suggest that
the ESC should continue as an organiser of surveys
and registries rather than of randomised trials and
should be more an advisory body than an oper-
ational entity. In this respect, the ESC may promote
European funding of clinical research. Creating an
ESC-driven research foundation remains beyond
reach for the moment.
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